COSCIENS Biopharma(CSCIF)
$5.73-0.05 (-0.95%)
CSCIF
COSCIENS Biopharma financials statements
$5.73
At close:-0.05 (-0.95%)
COSCIENS Biopharma (CSCIF) Ratios
903 Followers
COSCIENS Biopharma Ratios
CSCIF's free cash flow for Q3 2026 was $1.42M. For the 2026 fiscal year, CSCIF's free cash flow was decreased by $-107.90K and operating cash flow was $1.53M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.18 | 3.32 | 8.01 | 7.88 | 9.12 |
| Quick Ratio | 2.82 | 2.95 | 7.13 | 7.84 | 8.88 |
| Cash Ratio | 2.02 | 2.27 | 7.49 | 7.18 | 8.41 |
| Solvency Ratio | -0.53 | -0.63 | -0.19 | 0.16 | 0.10 |
| Operating Cash Flow Ratio | -2.39 | -2.02 | -3.77 | -1.94 | -1.10 |
| Short-Term Operating Cash Flow Coverage | -40.17 | 0.00 | -57.31 | -50.12 | -37.72 |
| Net Current Asset Value | $ -6.08M | $ 2.07M | $ 17.55M | $ 35.24M | $ 43.70M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.10 | 0.07 | 0.09 | 0.07 | 0.00 |
| Debt-to-Equity Ratio | 0.56 | 0.18 | 0.19 | 0.11 | 0.00 |
| Debt-to-Capital Ratio | 0.36 | 0.15 | 0.16 | 0.10 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.07 | 0.04 | 0.03 |
| Financial Leverage Ratio | 5.58 | 2.66 | 2.03 | 1.57 | 1.51 |
| Debt Service Coverage Ratio | -24.45 | -105.22 | -38.71 | -44.42 | 8.38 |
| Interest Coverage Ratio | -62.15 | -108.71 | -140.54 | -160.58 | -72.79 |
| Debt to Market Cap | 0.10 | 0.00 | 0.05 | 0.03 | 0.01 |
| Interest Debt Per Share | 6.59 | 0.94 | 0.72 | 0.81 | 0.06 |
| Net Debt to EBITDA | 0.55 | 1.04 | 1.70 | 3.04 | -22.85 |
| Profitability Margins | |||||
| Gross Profit Margin | 35.30% | 49.33% | 95.06% | 97.22% | 98.29% |
| EBIT Margin | -139.25% | -157.46% | -400.36% | 77.17% | 51.44% |
| EBITDA Margin | -123.41% | -140.70% | -400.00% | -272.36% | 54.20% |
| Operating Profit Margin | -139.25% | -146.27% | -400.36% | -272.64% | -164.85% |
| Pretax Profit Margin | -138.01% | -158.81% | -367.99% | -402.96% | -161.16% |
| Net Profit Margin | -138.14% | -159.68% | -78.93% | 57.46% | 50.18% |
| Continuous Operations Profit Margin | -138.14% | -159.68% | -78.93% | 57.46% | 50.18% |
| Net Income Per EBT | 100.10% | 100.55% | 21.45% | -14.26% | -31.14% |
| EBT Per EBIT | 99.11% | 108.57% | 91.91% | 147.80% | 97.76% |
| Return on Assets (ROA) | -49.27% | -43.65% | -9.59% | 5.78% | 3.30% |
| Return on Equity (ROE) | -274.82% | -116.32% | -19.51% | 9.06% | 4.98% |
| Return on Capital Employed (ROCE) | -59.73% | -50.36% | -55.45% | -31.39% | -11.99% |
| Return on Invested Capital (ROIC) | -59.02% | -49.87% | -49.62% | -31.05% | -11.84% |
| Return on Tangible Assets | -49.27% | -43.65% | -9.59% | 5.79% | 3.70% |
| Earnings Yield | -483.00% | -73.70% | -9.43% | 5.26% | 1.60% |
| Efficiency Ratios | |||||
| Receivables Turnover | 6.06 | 3.88 | 15.54 | 2.65 | 3.14 |
| Payables Turnover | 6.64 | 2.02 | 0.12 | 0.08 | 0.10 |
| Inventory Turnover | 3.78 | 1.81 | 0.06 | 0.69 | 0.05 |
| Fixed Asset Turnover | 0.78 | 0.87 | 14.19 | 26.11 | 27.40 |
| Asset Turnover | 0.36 | 0.27 | 0.12 | 0.10 | 0.07 |
| Working Capital Turnover Ratio | 0.62 | 0.39 | 0.11 | 0.10 | 0.12 |
| Cash Conversion Cycle | 101.70 | 115.41 | 3535.30 | -4068.06 | 3720.90 |
| Days of Sales Outstanding | 60.22 | 94.08 | 23.49 | 137.57 | 116.40 |
| Days of Inventory Outstanding | 96.47 | 202.19 | 6579.78 | 532.39 | 7392.40 |
| Days of Payables Outstanding | 54.99 | 180.85 | 3067.97 | 4738.03 | 3787.89 |
| Operating Cycle | 156.69 | 296.26 | 6603.28 | 669.96 | 7508.79 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -24.51 | -5.64 | -3.53 | -2.82 | -1.87 |
| Free Cash Flow Per Share | -26.56 | -6.09 | -3.53 | -2.82 | -2.01 |
| Dividend Paid and CapEx Coverage Ratio | -12.00 | -12.55 | -900.95 | -1243.64 | -13.43 |
| Capital Expenditure Coverage Ratio | -12.00 | -12.55 | -900.95 | -1243.64 | -13.43 |
| Operating Cash Flow Coverage Ratio | -4.02 | -6.31 | -5.05 | -3.54 | -53.30 |
| Operating Cash Flow to Sales Ratio | -1.13 | -1.52 | -3.81 | -2.43 | -1.63 |
| Free Cash Flow Yield | -428.03% | -75.72% | -45.54% | -22.22% | -5.58% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.21 | -1.36 | -4.04 | 6.79 | 27.05 |
| Price-to-Sales (P/S) Ratio | 0.29 | 2.17 | 8.37 | 10.92 | 31.44 |
| Price-to-Book (P/B) Ratio | 0.57 | 1.58 | 2.07 | 1.72 | 3.12 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.23 | -1.32 | -2.20 | -4.50 | -17.94 |
| Price-to-Operating Cash Flow Ratio | -0.25 | -1.43 | -2.20 | -4.50 | -19.27 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.01 | 0.02 | 0.17 | 0.27 |
| Enterprise Value Multiple | 0.32 | -0.50 | -0.39 | -0.97 | 35.16 |
| Enterprise Value | -2.97M | 6.69M | 7.01M | 14.86M | 100.22M |
| EV to EBITDA | 0.32 | -0.50 | -0.39 | -0.97 | 35.16 |
| EV to Sales | -0.39 | 0.70 | 1.56 | 2.64 | 19.05 |
| EV to Free Cash Flow | 0.32 | -0.43 | -0.41 | -1.09 | -10.87 |
| EV to Operating Cash Flow | 0.34 | -0.46 | -0.41 | -1.09 | -11.68 |
| Tangible Book Value Per Share | 10.90 | 5.10 | 3.75 | 7.36 | 9.62 |
| Shareholders’ Equity Per Share | 10.90 | 5.10 | 3.75 | 7.37 | 11.53 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | -0.01 | 0.09 | -0.04 | 0.01 |
| Revenue Per Share | 21.69 | 3.71 | 0.93 | 1.16 | 1.14 |
| Net Income Per Share | -29.97 | -5.93 | -0.73 | 0.67 | 0.57 |
| Tax Burden | 1.00 | 1.01 | 0.21 | -0.14 | -0.31 |
| Interest Burden | 0.99 | 1.01 | 0.92 | -5.22 | -3.13 |
| Research & Development to Revenue | 0.39 | 0.87 | 3.01 | 2.22 | 1.25 |
| SG&A to Revenue | 1.34 | 1.09 | 1.94 | 1.46 | 1.38 |
| Stock-Based Compensation to Revenue | 0.00 | 0.05 | 0.04 | 0.01 | 0.00 |
| Income Quality | 0.82 | 0.95 | 4.82 | -4.22 | -3.25 |
Currency in USD

